Ser325
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser325  -  CXCR4 (human)

Site Information
tsVsRGssLkILskG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3849622

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 4 ) , immunoassay ( 2 ) , immunoprecipitation ( 2 , 21 ) , mass spectrometry ( 6 , 10 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 ) , mutation of modification site ( 2 , 21 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 8 , 15 , 18 , 21 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 15 , 18 , 21 )
Disease tissue studied:
breast cancer ( 15 ) , cervical cancer ( 19 ) , cervical adenocarcinoma ( 19 ) , leukemia ( 3 ) , chronic lymphocytic leukemia ( 4 ) , T cell leukemia ( 3 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , non-small cell lung adenocarcinoma ( 5 ) , non-small cell large cell lung carcinoma ( 5 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
CXCL12 (human) ( 3 ) , PKCA (human) ( 2 )
Putative in vivo kinases:
GRK6 (human) ( 2 , 18 ) , PKCD (human) ( 18 )
Treatments:
AG1478 ( 15 ) , antibody ( 4 ) , ATI-2341 ( 1 , 8 ) , Bis_V ( 18 ) , bisindolylmaleimide ( 18 ) , CID755673 ( 4 ) , CXCL12 ( 1 , 2 , 8 , 15 , 18 , 21 ) , GF109203X ( 2 , 8 ) , Go_6976 ( 18 ) , heregulin ( 15 ) , IL-24 ( 5 ) , nocodazole ( 19 ) , peptide_antagonist ( 18 ) , phorbol_ester ( 2 ) , plerixafor ( 3 , 15 ) , rottlerin ( 18 ) , siRNA ( 2 ) , X4-2-6 ( 3 )

Downstream Regulation
Effects of modification on CXCR4:
activity, induced ( 21 ) , enzymatic activity, induced ( 2 ) , intracellular localization ( 21 ) , molecular association, regulation ( 21 ) , protein degradation ( 2 , 21 ) , receptor desensitization, induced ( 2 ) , receptor internalization, induced ( 2 , 3 ) , ubiquitination ( 2 , 21 )
Effects of modification on biological processes:
endocytosis, induced ( 1 )
Induce interaction with:
ITCH (human) ( 21 )

References 

1

Luo J, et al. (2021) Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4. J Biol Chem 298, 101551
34973340   Curated Info

2

Caballero A, et al. (2019) Heterologous regulation of CXCR4 lysosomal trafficking. J Biol Chem 294, 8023-8036
30936203   Curated Info

3

Hitchinson B, et al. (2018) Biased antagonism of CXCR4 avoids antagonist tolerance. Sci Signal 11
30327409   Curated Info

4

Saint-Georges S, et al. (2016) Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia. Oncotarget 7, 41031-41046
27127886   Curated Info

5

Panneerselvam J, et al. (2015) IL-24 Inhibits Lung Cancer Cell Migration and Invasion by Disrupting The SDF-1/CXCR4 Signaling Axis. PLoS One 10, e0122439
25775124   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Chandrasekaran P, et al. (2014) HIV-1 Nef down-modulates C-C and C-X-C chemokine receptors via ubiquitin and ubiquitin-independent mechanism. PLoS One 9, e86998
24489825   Curated Info

8

Quoyer J, et al. (2013) Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A 110, E5088-97
24309376   Curated Info

9

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

10

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

11

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

12

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

13

Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

14

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

15

Sosa MS, et al. (2010) Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 40, 877-92
21172654   Curated Info

16

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

17

Possemato A (2010) CST Curation Set: 9348; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

18

Busillo JM, et al. (2010) Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling. J Biol Chem 285, 7805-17
20048153   Curated Info

19

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

20

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

21

Bhandari D, Robia SL, Marchese A (2009) The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to the chemokine receptor CXCR4 via a novel WW domain-mediated interaction. Mol Biol Cell 20, 1324-39
19116316   Curated Info

22

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

23

Farnsworth C (2009) CST Curation Set: 6186; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

24

Farnsworth C (2009) CST Curation Set: 6185; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

25

Zhou J (2009) CST Curation Set: 5902; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

26

Zhou J (2009) CST Curation Set: 5903; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info